<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065711</url>
  </required_header>
  <id_info>
    <org_study_id>2019-002</org_study_id>
    <nct_id>NCT04065711</nct_id>
  </id_info>
  <brief_title>Study of the Soliton Rapid Acoustic Pulse (RAP) Device for the Treatment of Cellulite</brief_title>
  <official_title>Multi-Center Study of the Soliton Rapid Acoustic Pulse (RAP) Device for the Treatment of Cellulite</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soliton</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soliton</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, and efficacy of Soliton's Rapid Acoustic Pulse (RAP) device for the
      temporary improvement in the appearance of cellulite.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-site clinical study to evaluate the safety, efficacy and tolerability of Soliton's
      Rapid Acoustic Pulse (RAP) device fo the temporary improvement in the appearance of
      cellulite.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedure Safety- All treated participants are free from unexpected adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary objective is to demonstrate freedom from unexpected adverse
events (UAEs) and serious adverse events (SAEs) directly attributable to the RAP device or treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RAP treatment effectiveness</measure>
    <time_frame>12 weeks, 26 weeks and 52 weeks</time_frame>
    <description>To demonstrate temporary improvement in the appearance of cellulite as determined by blinded independent physician assessment (IPA) correctly identifying the 12-week post-treatment photographs from randomly placed side-by-side comparison of before and after photographs.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Cellulite</condition>
  <arm_group>
    <arm_group_label>RAP Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each treatment area will receive 30-40 minutes (30-40 individual doses) of RAP treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Soliton's Rapid Acoustic Pulse (RAP)</intervention_name>
    <description>Treatment for the temporary improvement in the appearance of cellulite.</description>
    <arm_group_label>RAP Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female ages 18-50 years

          -  Seeking treatment of cellulite in the thigh and/or buttock areas

          -  Area of severe cellulite on the thigh and/or buttock with an average simplified
             Cellulite Severity Scale at Baseline ≥ 4.0 (Table 2)

          -  Having at least one dimple, or ridge-depression, in the treatment area, with a depth
             of approximately 5 mm or greater.

          -  Stable weight nominally +/- 5% for at least the past 6 months.

          -  Body Mass Index (B.M.I.) is ≤ 30

          -  Participant will not have had invasive or energy based cellulite treatments
             (liposuction, subcision, RF, laser, ESWT, etc.) for the prior 12 months.

          -  Participant will not have used topical based cellulite treatments for prior 6 months
             and will not use during the trial.

          -  Will not undergo any other cellulite treatments for a period of 12 months following
             RAP treatment.

          -  Participant is willing to participate in study and adhere to follow-up schedule

          -  Participant is able to read and comprehend English

          -  Participant has completed the Informed Consent Form

        Exclusion Criteria:

          -  Participant is unwilling to have research photos taken of treatment areas in the
             presence of Sponsor's researchers.

          -  Participant is unwilling to have RAP treatment provided in the presence of Sponsor's
             researchers.

          -  Participant is pregnant or planning to become pregnant during the duration of the
             study.

          -  Has atrophic scars, or has a history of atrophic scars or keloids.

          -  Tattoo or former tattoo at or near treatment area.

          -  Metal or plastic implants in the area of the treatment (vascular stent, or implants in
             the hips, knees, etc.).

          -  Active electronic implants such as pacemakers, defibrillators, cochlear implants,
             nerve/brain stimulators, drug pump, etc.

          -  Medical disorder that would hinder the wound healing or immune response (no blood
             disorder, inflammatory disease, etc.).

          -  History of coagulopathy(ies) and/or on anticoagulant medication.

          -  Skin disorders (skin infections or rashes, extensive scarring, psoriasis, etc.) in the
             treatment area.

          -  Current smoker.

          -  Any surgical procedure in the prior 3 months, or planned during the duration of the
             study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>This study is specific to females ages 18-50 years.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Capelli, MD</last_name>
    <role>Study Director</role>
    <affiliation>Soliton, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clear Dermatology and Aesthetics Center Investigate MD</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Cosmetic Surgery &amp; Dermatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Laser and Skin Care</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SkinCare Physicians</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

